Nuvalent (NUVL) Projected to Post Earnings on Thursday

Nuvalent (NASDAQ:NUVL) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Nuvalent to post earnings of ($1.48) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Nuvalent Price Performance

Shares of Nuvalent stock opened at $102.36 on Thursday. Nuvalent has a 1-year low of $55.53 and a 1-year high of $113.01. The business’s fifty day moving average price is $103.53 and its two-hundred day moving average price is $93.85. The company has a market capitalization of $7.44 billion, a P/E ratio of -19.24 and a beta of 1.32.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Barclays set a $152.00 target price on Nuvalent in a report on Monday, November 17th. Stifel Nicolaus raised their price objective on Nuvalent from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Guggenheim lifted their target price on Nuvalent from $125.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. HC Wainwright upped their target price on Nuvalent from $130.00 to $155.00 and gave the company a “buy” rating in a report on Monday, November 17th. Finally, Wedbush reissued an “outperform” rating and issued a $125.00 price target (up previously from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. Fifteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nuvalent has a consensus rating of “Moderate Buy” and an average price target of $138.33.

Insiders Place Their Bets

In related news, Director James E. Flynn sold 742,574 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $95.44, for a total value of $70,871,262.56. Following the completion of the transaction, the director directly owned 8,299,225 shares in the company, valued at approximately $792,078,034. The trade was a 8.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James Richard Porter sold 17,890 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $1,741,054.80. Following the transaction, the chief executive officer owned 288,172 shares of the company’s stock, valued at approximately $28,044,899.04. The trade was a 5.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 826,537 shares of company stock worth $79,414,026 over the last ninety days. 10.20% of the stock is owned by insiders.

Institutional Trading of Nuvalent

A number of institutional investors have recently made changes to their positions in NUVL. US Bancorp DE lifted its position in Nuvalent by 10.0% during the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after buying an additional 188 shares in the last quarter. Portland Investment Counsel Inc. acquired a new stake in Nuvalent in the fourth quarter valued at $201,000. FORA Capital LLC bought a new position in shares of Nuvalent in the 4th quarter valued at about $218,000. Tower Research Capital LLC TRC increased its stake in shares of Nuvalent by 23.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,142 shares of the company’s stock worth $240,000 after purchasing an additional 588 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in shares of Nuvalent in the 4th quarter valued at about $251,000. Institutional investors own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.